NCT07465289

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

A Phase 3, Open-Label, Extension Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.

Conditions

• Ocular Myasthenia Gravis

Interventions

Type	Name	Description
DRUG	Rozanolixizumab	Rozanolixizumab will be administered by subcutaneous infusion.

Timeline

• Start date: 2026-07-27
• Primary completion: 2031-01-23
• Completion: 2031-01-23
• First posted: 2026-03-11
• Last updated: 2026-03-11

Regulatory

• FDA-regulated drug study